| A Systematic Review of Cost-of-Illness Studies of Multimorbidity |
22 |
| Opportunities for Use of Blockchain Technology in Medicine |
16 |
| Striving for a Societal Perspective: A Framework for Economic Evaluations When Costs and Effects Fall on Multiple Sectors and Decision Makers |
15 |
| Healthcare Finance in the Kingdom of Saudi Arabia: A Qualitative Study of Householders' Attitudes |
12 |
| The Economic Burden of Abuse of Prescription Opioids: A Systematic Literature Review from 2012 to 2017 |
11 |
| An Updated Systematic Review of Studies Mapping (or Cross-Walking) Measures of Health-Related Quality of Life to Generic Preference-Based Measures to Generate Utility Values |
10 |
| Friction Cost Estimates of Productivity Costs in Cost-of-Illness Studies in Comparison with Human Capital Estimates: A Review |
10 |
| SecurAcath for Securing Peripherally Inserted Central Catheters: A NICE Medical Technology Guidance |
10 |
| Trends and Factors Associated with Hospitalization Costs for Inflammatory Bowel Disease in the United States |
10 |
| Standardized Questionnaire for the Measurement, Valuation, and Estimation of Costs of Informal Care Based on the Opportunity Cost and Proxy Good Method |
7 |
| Investigating the Willingness to Pay for a Contributory National Health Insurance Scheme in Saudi Arabia: A Cross-sectional Stated Preference Approach |
7 |
| Costs in the Treatment of Schizophrenia in Adults Receiving Atypical Antipsychotics: An 11-Year Cohort in Brazil |
7 |
| Cost Effectiveness of Dialysis Modalities: A Systematic Review of Economic Evaluations |
7 |
| Efficiency Measurement in Health Facilities: A Systematic Review in Low- and Middle-Income Countries |
7 |
| A Review of Recent Decision-Analytic Models Used to Evaluate the Economic Value of Cancer Treatments |
6 |
| Projecting Pharmaceutical Expenditure in EU5 to 2021: Adjusting for the Impact of Discounts and Rebates |
5 |
| Estimation of the Direct Cost of Poliomyelitis Rehabilitation Treatment to Pakistani Patients: A 53-Year Retrospective Study |
5 |
| Modelled Economic Evaluation of Nivolumab for the Treatment of Second-Line Advanced or Metastatic Squamous Non-Small-Cell Lung Cancer in Australia Using Both Partition Survival and Markov Models |
5 |
| Family Spillover Effects in Pediatric Cost-Utility Analyses |
5 |
| Sugar-Sweetened Beverage Demand and Tax Simulation for Federal Food Assistance Participants: A Case of Two New England States |
4 |
| Multi-indication and Combination Pricing and Reimbursement of Pharmaceuticals: Opportunities for Improved Health Care through Faster Uptake of New Innovations |
4 |
| A Payer Perspective of the Hospital Inpatient Additional Care Costs of Antimicrobial Resistance in France: A Matched Case-Control Study |
4 |
| Cost-Consequence Analysis Alongside a Randomised Controlled Trial of Hospital Versus Telephone Follow-Up after Treatment for Endometrial Cancer |
4 |
| A Review of the Development and Application of Generic Preference-Based Instruments with the Older Population |
4 |
| Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia |
4 |
| Shaping Pharmaceutical Tenders for Effectiveness and Sustainability in Countries with Expanding Healthcare Coverage |
3 |
| A Framework to Prioritise Health Research Proposals for Funding: Integrating Value for Money |
3 |
| Peristeen Transanal Irrigation System to Manage Bowel Dysfunction: A NICE Medical Technology Guidance |
3 |
| Reliability and Validity of the Contingent Valuation Method for Estimating Willingness to Pay: A Case of In Vitro Fertilisation |
3 |
| A Review of the Challenges of Using Biomedical Big Data for Economic Evaluations of Precision Medicine |
3 |
| A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand |
3 |
| EMA and NICE Appraisal Processes for Cancer Drugs: Current Status and Uncertainties |
3 |
| Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis |
3 |
| Cost-Effectiveness Analysis of Early Treatment of Chronic HCV with Sofosbuvir/Velpatasvir in Italy |
3 |
| Cost of Illness for Five Major Foodborne Illnesses and Sequelae in Sweden |
3 |
| Economic Evaluations of Guideline-Based Care for Chronic Wounds: a Systematic Review |
3 |
| The Impact of Patent Expiry on Drug Prices: A Systematic Literature Review |
3 |
| Impact of Reducing Glycated Hemoglobin on Healthcare Costs Among a Population with Uncontrolled Diabetes |
3 |
| The Real-World Cost-Effectiveness of Coronary Artery Bypass Surgery Versus Stenting in High-Risk Patients: Propensity Score-Matched Analysis of a Single-Centre Experience |
3 |
| Health Technology Assessment as Part of a Broader Process for Priority Setting and Resource Allocation |
3 |
| Involving Members of the Public in Health Economics Research: Insights from Selecting Health States for Valuation to Estimate Quality-Adjusted Life-Year (QALY) Weights |
3 |
| Cost Analysis of Tuberculosis Diagnosis in Cambodia with and without Xpert (R) MTB/RIF for People Living with HIV/AIDS and People with Presumptive Multidrug-resistant Tuberculosis |
3 |
| Using Post-market Utilisation Analysis to Support Medicines Pricing Policy: An Australian Case Study of Aflibercept and Ranibizumab Use |
2 |
| Cost-Effectiveness of Obinutuzumab in Combination with Bendamustine Followed by Obinutuzumab Maintenance versus Bendamustine Alone in Treatment of Patients with Rituximab-Refractory Follicular Lymphoma in Norway |
2 |
| Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16) |
2 |
| General Trends in Prices and Prescription Patterns of Anticonvulsants in Germany between 2000 and 2017: Analysis of National and Cohort-Based Data |
2 |
| Treatment Patterns, Overall Survival, and Total Healthcare Costs of Advanced Merkel Cell Carcinoma in the USA |
2 |
| Development of Conversion Functions Mapping the FACT-B Total Score to the EQ-5D-5L Utility Value by Three Linking Methods and Comparison with the Ordinary Least Square Method |
2 |
| Association Between Medicare's Mandatory Hospital Value-Based Purchasing Program and Cost Inefficiency |
2 |
| Consequences of Biomarker Analysis on the Cost-Effectiveness of Cetuximab in Combination with FOLFIRI as a First-Line Treatment of Metastatic Colorectal Cancer: Personalised Medicine at Work |
2 |
